Back to mobile site

Oppenheimer on Allogene (ALLO): 'data represents strong early validation of the ALPHA3 strategy'

April 13, 2026 12:04 PM EDT Send to a Friend
Oppenheimer analyst Matt Biegler reiterated an Outperform rating and $7.00 price target on Allogene (NASDAQ: ALLO)The analyst commented, "Allogene reported ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login